Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 1, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: July 28, 2005
- Previous Holdings: 18,336,331 ADRs
- New Holdings: 18,317,801 ADRs
- Average Price: $47.00
- Reason: A movement in the fund.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It notes that the Plan is a discretionary fund for employees and former employees. Two directors, Dr. J P Garnier and Dr. T Yamada, are potentially interested in the shares held in the fund in the same manner as other employees.
Key Facts for Investor Verification
- The reduction in ADR holdings (18,530 shares) was due to a fund movement, not necessarily a direct sale by directors.
- Directors Dr. J P Garnier and Dr. T Yamada have potential interests in the fund but are not explicitly stated to have directed the transaction.
- The transaction was notified under Disclosure rule 3.1.4R(1)(b).
- No financial performance data is included in this specific filing.